| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45c0430dd45ca6c64640c228acd8a48c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d7d01a342033dd8cd30e47e501e5045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8286cb471867930f68f900ce1c3fcf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4bd0d4bef63c57f5d9bbafc9bd90c93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91140fa80c408f2877f254eb435e8694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c072abef42681dcc5502f506b065b63 |
| publicationDate |
2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2645872-T3 |
| titleOfInvention |
Method for the identification of a patient's sensitivity to telomerase inhibition therapy |
| abstract |
A method for identifying the probability of a mammalian subject having an adverse reaction to telomerase inhibition therapy comprising, (a) determining the average or median length of telomeres in a biological sample comprising cells obtained from the mammalian subject before or at the time of treatment with a telomerase inhibition therapy and the multiplication of the average or median length of the telomeres by a coefficient to reach a component of the telomere length; (b) the multiplication of the expected treatment dose by a coefficient to reach a dosage component; and (c) produce the sum of the telomere component, the dosage component and a constant; and (d) the determination of the expected probability of an adverse reaction in the mammalian subject from treatment with telomerase inhibition therapy. |
| priorityDate |
2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |